CH678490A5 - - Google Patents

Download PDF

Info

Publication number
CH678490A5
CH678490A5 CH4684/88A CH468488A CH678490A5 CH 678490 A5 CH678490 A5 CH 678490A5 CH 4684/88 A CH4684/88 A CH 4684/88A CH 468488 A CH468488 A CH 468488A CH 678490 A5 CH678490 A5 CH 678490A5
Authority
CH
Switzerland
Prior art keywords
medicament according
hydroxylysine
medicament
acid addition
dimethylaminoethanol
Prior art date
Application number
CH4684/88A
Other languages
German (de)
Inventor
Wilhelm Dr Med Hoerrmann
Original Assignee
Hoerrmann Wilhelm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoerrmann Wilhelm filed Critical Hoerrmann Wilhelm
Publication of CH678490A5 publication Critical patent/CH678490A5/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate

Description

CH678 490A5 CH678 490A5

Beschreibung description

Die Erfindung betrifft ein Arzneimittel, das als Wirksubstanz mindestens ein Isomeres des Hydroxyly-sins oder Lysins oder deren pharmazeutisch annehmbare Abkömmlinge, gegebenenfalls zusammen mit üblichen Trägern und/oder Hilfsmitteln enthält. Dabei ist zu beachten, dass das Isomere des Hydroxyly-sins oder Lysins in der L- oder D-Konfiguration vorliegen kann, wobei die L-Konfiguration bevorzugt ist, dass die Hydroxylgruppe sich von beta bis delta an verschiedenen Stellen der Kohlenstoffkette befinden kann, wobei die delta-Position bevorzugt ist und bezüglich der stereoisomeren Stellung der Hydroxylgruppe an einem asymmetrischen Kohlenstoffatom beide Isomere pharmazeutisch von Bedeutung sind. The invention relates to a medicament which contains at least one isomer of hydroxylysine or lysine or its pharmaceutically acceptable derivatives, optionally together with conventional carriers and / or auxiliaries, as the active substance. It should be noted here that the isomer of hydroxylysine or lysine can be in the L or D configuration, the L configuration being preferred so that the hydroxyl group can be located at various points in the carbon chain from beta to delta, where the delta position is preferred and both isomers are pharmaceutically important with regard to the stereoisomeric position of the hydroxyl group on an asymmetric carbon atom.

Die Wirkung dieser Arzneimittel kann durch die Zugabe von N-Methyl-aminoäthanol und/oder N-Di-methyl-aminoäthanol, z.B. in Form ihrer Säureadditionssalze gesteigert werden. The effect of these drugs can be increased by the addition of N-methylaminoethanol and / or N-dimethylaminoethanol, e.g. be increased in the form of their acid addition salts.

Die Strukturformeln dieser an sich bekannten Verbindungen werden hier nur der Vollständigkeit halberwiedergegeben. The structural formulas of these known compounds are only given here for the sake of completeness.

CH 678 490 A5 CH 678 490 A5

25 25th

30 30th

35 35

HOOC OH HOOC OH

i I i I

H-C-CH2-CH2-C-CH2"NH2 H-C-CH2-CH2-C-CH2 "NH2

* 1 * 1

H„N H H "N H

10 2 10 2

15 15

HOOC H HOOC H

i ! i!

20 H-C-CH2-CH2-C-CH2-NH2 20 H-C-CH2-CH2-C-CH2-NH2

I I.

H2N OH H2N OH

HOOC i HOOC i

HC-CH2-CH2-CH2-CH2-NH2 HC-CH2-CH2-CH2-CH2-NH2

40 H2N 40 H2N

45 H 45 h

50 50

55 55

+ +

(H3C-N-CH2"CH20H) (H3C-N-CH2 "CH20H)

N N

CH3 CH3

x- x-

i i

60 (H-N-CH2-CH2OH) x- 60 (H-N-CH2-CH2OH) x-

CH-, CH-,

65 65

3 3rd

5 5

"10 "10

15 15

20 20th

25 25th

30 30th

35 35

40 40

45 45

50 50

55 55

60 60

CH 678 490 A5 CH 678 490 A5

Die genannten Verbindungen sind als solche bekannt und können nach an sich bekannten Verfahren hergestellt werden. The compounds mentioned are known as such and can be prepared by processes known per se.

Die erfindungsgemässen Arzneimittel können die Isomere des Hydroxylysins oder Lysins auch in Form von pharmazeutisch verträglichen Abkömmlingen enthalten, besonders solche, die im Körper in die freie Form der Derivate übergehen. Dazu gehören insbesondere Alkalisalze, Erdalkalisalze, Säureadditionssatze, Ester, Amide und Äther von Hydroxylysin oder Lysin und deren N-alkyl-Derivate sowie Oli-go- oder Polypeptide davon. The medicaments according to the invention can also contain the isomers of hydroxylysine or lysine in the form of pharmaceutically acceptable derivatives, especially those which are converted into the free form of the derivatives in the body. These include, in particular, alkali metal salts, alkaline earth metal salts, acid addition sets, esters, amides and ethers of hydroxylysine or lysine and their N-alkyl derivatives as well as oligo-go or polypeptides thereof.

Die erfindungsgemässen Arzneimittel dienen der Behandlung der nachfolgend aufgeführten Erkrankungen, sei es durch ihre alleinige Gäbe oder zur Unterstützung herkömmlicher Therapie. Die herkömmliche Therapie ist in vielen Fällen unbefriedigend, was schon daraus hervorgeht, dass in einer nicht kleinen Zahl von Fällen operative Eingriffe heute noch unumgänglich sind. The medicaments according to the invention are used to treat the diseases listed below, be it through their sole administration or to support conventional therapy. Conventional therapy is unsatisfactory in many cases, which is clear from the fact that surgical interventions are still unavoidable in a small number of cases.

Anwendungsgebiete der erfindungsgemässen Arzneimittel: Areas of application of the medicaments according to the invention:

1. Venenerkrankungen: Hierzu gehören vor allem Erweiterungen und entzündliche Veränderungen der Venen sowie Varicocoelen und Hämorrhoiden, ausserdem Hirnsinuserkrankungen und verwandte Krankheitsbilder. 1. Venous disorders: These primarily include dilatation and inflammatory changes in the veins as well as varicocoeles and hemorrhoids, as well as brain sinus disorders and related clinical pictures.

2. Herzerkrankungen: Vor allem Endocarditis und Folgen sowie Myocarditis und Folgen, wozu bei letzteren vor allem Herzrhythmusstörungen zu nennen sind. 2. Heart diseases: Above all endocarditis and consequences as well as myocarditis and consequences, for which the cardiac arrhythmias are particularly noteworthy.

3. Scharlach, Rheumatisches Fieber, Septische Gelenkerkrankungen, Erysipel Impetigo usw. 3. Scarlet fever, rheumatic fever, septic joint diseases, erysipelas impetigo etc.

4. Prostatitis und Adnexitis. 4. Prostatitis and adnexitis.

5. Analfissuren. 5. Anal fissures.

6. Zahncaries. 6. Dental caries.

7. Neurologische Erkrankungen, insbesondere solche, die mit Störungen der Motorik und Sensibilität einhergehen. 7. Neurological diseases, especially those associated with motor disorders and sensitivity disorders.

8. Hernien. 8. Hernias.

Das Wirkprinzip in allen obengenannten Fällen liegt in einer durch die erfindungsgemässen Arzneimit-tef bewirkten Stärkung von intra- und extrazellulären.Fasersystemen. The principle of action in all the above-mentioned cases lies in the strengthening of intra- and extracellular fiber systems brought about by the medicament according to the invention.

Die erfindungsgemässen Arzneimittel werden in grundsätzlich gleicher Weise verabreicht wie die gewöhnlichen Aminosäuren, also bevorzugt peroral oder intravenös, bzw. zentralintravenös. Auch die Zufuhrin Tabletten, Dragées, Injektions- und Infusionslösungen ist die gleiche. The medicaments according to the invention are administered in basically the same way as the usual amino acids, that is to say preferably orally or intravenously or centrally intravenously. The supply of tablets, dragees, injection and infusion solutions is the same.

Bei oberflächlichen gut zugänglichen Krankheitsherden kommt auch die örtliche Anwendung als Lösung, oder Puder, oder Salbe, oder dergleichen in Betracht. In the case of easily accessible foci of disease, topical application as a solution, or powder, or ointment, or the like, also comes into consideration.

Da es sich um untoxische Verbindungen handelt, kann sich die Dosierung in einem weiten Bereich bewegen, wobei man die übliche therapeutische Aminosäure-Dosierung mit 0,01 bis 0,1 g pro kg und Substanz auch hier zu Grunde legen kann.- Since these are non-toxic compounds, the dosage can vary within a wide range, whereby the usual therapeutic amino acid dosage of 0.01 to 0.1 g per kg and substance can also be used as a basis.

Die für alle Aminosäuren geltenden Kontraindikationen sind auch hier zu beachten. The contraindications that apply to all amino acids must also be observed here.

Die pharmazeutische Herstellung und Verarbeitung erfolgt in allgemein üblicher Weise und berücksichtigt die gesetzlichen Bestimmungen in Hinsicht auf Substanzreinheit, Sterilität, Pyrogenfreiheit usw. The pharmaceutical production and processing takes place in a generally customary manner and takes into account the legal provisions with regard to substance purity, sterility, freedom from pyrogens, etc.

Claims (6)

PatentansprücheClaims 1. Arzneimittel, enthaltend als Wirksubstanz mindestens ein a-, ß-, y- oder 5-lsomeres des Hydroxylysins in D- oder L-Form, oder ein Alkalisalz, Erdaikalisalz, Säureadditionssalz, Ester, Amid, Äther, N-Alkyl-Derivat oder ein Peptid davon.1. Medicament containing as active substance at least one a, β, y or 5 isomer of hydroxylysine in D or L form, or an alkali salt, alkaline earth salt, acid addition salt, ester, amide, ether, N-alkyl derivative or a peptide thereof. 2. Arzneimittel nach Anspruch 1, dadurch gekennzeichnet, dass das Hydrolysin in der L-Form vorliegt.2. Medicament according to claim 1, characterized in that the hydrolysin is in the L-form. 3. Arzneimittel nach einem der Ansprüche 1-2, dadurch gekennzeichnet, dass sich die Hydroxylgruppe des Hydroxylysins in delta-Position befindet.3. Medicament according to one of claims 1-2, characterized in that the hydroxyl group of the hydroxylysine is in the delta position. 4. Arzneimittel nach einem der Ansprüche 1-3, dadurch gekennzeichnet, dass die Wirksubstanz zusammen mit Trägern und/oder Hilfsmitteln vorliegt.4. Medicament according to one of claims 1-3, characterized in that the active substance is present together with carriers and / or auxiliaries. 5. Arzneimittel nach einem der Ansprüche 1-4, dadurch gekennzeichnet, dass sie zur Unterstützung der Wirkung N-Methyl-aminoäthanoI und/oder N-Dimethyl-aminoäthanol enthalten.5. Medicament according to one of claims 1-4, characterized in that it contains N-methylaminoethanol and / or N-dimethylaminoethanol to support the effect. 6. Arzneimittel nach einem der Ansprüche 1-5, dadurch gekennzeichnet, dass sie zur Unterstützung der Wirkung N-Methyl-aminoäthanoI und/oder N-Dimethylaminoäthanol in Form ihrer Säureadditionssalze enthalten.6. Medicament according to one of claims 1-5, characterized in that they contain N-methylaminoethanoI and / or N-dimethylaminoethanol in the form of their acid addition salts to support the effect. 44th
CH4684/88A 1987-12-30 1988-12-21 CH678490A5 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3744542A DE3744542B4 (en) 1987-12-30 1987-12-30 Pharmaceutical use of L-δ-hydroxylysine

Publications (1)

Publication Number Publication Date
CH678490A5 true CH678490A5 (en) 1991-09-30

Family

ID=6343857

Family Applications (1)

Application Number Title Priority Date Filing Date
CH4684/88A CH678490A5 (en) 1987-12-30 1988-12-21

Country Status (3)

Country Link
CH (1) CH678490A5 (en)
DE (1) DE3744542B4 (en)
GB (1) GB2226759A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3912477A1 (en) * 1989-04-15 1990-10-18 Mueller Robert Dr OUTSTANDING PRAEPARATE AND ITS USE
IT1407715B1 (en) * 2010-06-18 2014-04-30 Alphrema Srl COMPOSITIONS FOR TOPICAL USE FOR PROPHYLAXIS AND HYGIENIC TREATMENT OF SOME PROBLEMS OF ANO-RECTAL PATHOLOGY, LIKE HEMORROIDES, RAGADI, ASCESSES AND FISTULAS.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6588M (en) * 1967-10-11 1968-12-30
GB1219869A (en) * 1968-07-24 1971-01-20 Farmaceutici Italia Stabilized estrogen sulphate salts
GB1399887A (en) * 1971-06-10 1975-07-02 Prockop D J Composition and methods for controlling collagen synthesis
BE789856A (en) * 1971-10-13 1973-02-01 Tixier Georges MEDICINAL PRODUCT BASED ON LYSINE DERIVATIVES, WHICH MAY STIMULATE DIFFERENT METABOLISMS, IN PARTICULAR LEUKOCYTE GENESIS
JPS60243028A (en) * 1984-04-28 1985-12-03 Kyowa Hakko Kogyo Co Ltd Solubilization of interferon
FR2587900B1 (en) * 1985-10-01 1988-10-07 Morelle Jean BASIC FATTY-AMINO ACID ASSOCIATIONS WITH EMOLLIENT, EMULSIFIING AND ANTIOXIDANT PROPERTIES FOR COSMETICS, DERMATOLOGY AND FOOD
DE3728852C2 (en) * 1987-08-28 2003-06-18 Wilhelm Hoerrmann Medicines for tumor therapy

Also Published As

Publication number Publication date
GB8900048D0 (en) 1989-03-01
GB2226759A (en) 1990-07-11
DE3744542B4 (en) 2004-06-03
DE3744542A1 (en) 1989-07-13

Similar Documents

Publication Publication Date Title
DE69822665T2 (en) USE OF 9-DESOXY-2 ', 9-ALPHA-METHANO-3-OXA-4,5,6-TRINOR-3,7- (1', 3'-INTERPHENYLENE) -13,14-DIHYDROPROSTAGLANDIN-F1 FOR TREATMENT OF PERIPHERAL VASCULAR DISEASES
DE2817358C2 (en)
DE69732049T2 (en) PHARMACEUTICAL PREPARATIONS, CONTAINING SALTS OF HYALURONIC ACID AND LOCAL ANESTHETICS
DE2911670A1 (en) MEDICINES FOR THE THERAPEUTIC TREATMENT OF PERIPHERAL VASCULAR DISEASES
DE2903558A1 (en) THERAPEUTIC METHOD OF TREATMENT OF HYPERLIPOPROTEINEMIA AND HYPERLIPIDAEMIA, AND MEDICINAL PRODUCTS FOR ITS PERFORMANCE
DE2903579A1 (en) USE OF ACETYL CARNITINE AND OTHER ACYLDER DERIVATIVES OF CARNITINE FOR THE TREATMENT OF HYPERLIPOPROTEINEMIC AND HYPERLIMPIDAEMIA AND MEDICINAL PRODUCTS
DE3235093A1 (en) ANTIPARKINSON AGENTS
EP0185210B1 (en) Use of dipeptide derivatives for the preparation of medicaments for the treatment of sufferers from amyotrophic lateral sclerosis
EP0752246A2 (en) Kappa opiate agonists for inflammatory gut diseases
EP0530446A2 (en) Use of sulfur containing carboxylic acids for combatting pathophysiologic excitatory disorders and related diseases as well as allergic diseases and their preparation as medicament
DE3726945A1 (en) L-Carnitine derivatives of valproic acid and pharmaceuticals containing these
CH667591A5 (en) MEDICATIONS CONTAINING HYDROXYPROLINE.
DE3619426A1 (en) AGENT FOR INCREASING RESISTANCE TO COLD DISEASES IN PATIENTS WITH RESTRICTED LUNG FUNCTION
DE2820794C2 (en) Salts of (-Hcis) -l ^ -epoxypropylphosphonic acid, process for their preparation and pharmaceutical preparation containing them
DE2528609A1 (en) DERIVATIVES OF APOVINCAMIC ACIDS
CH678490A5 (en)
DE3525390C2 (en)
DE3202561A1 (en) Lysine salts of [(1-benzyl-1H-indazol-3-yl)oxy]acetic acid, process for their preparation and pharmaceuticals containing these
DE2335729A1 (en) VINCANOL SALT, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS AS ACTIVE SUBSTANCES
DE3011274A1 (en) SYNERGISTIC RADIATION PROTECTIVE PHARMACEUTICAL PREPARATIONS AND THEIR PRODUCTION
EP0223850B1 (en) Medicines which contain derivatives of proline or hydroxyproline
DE2131679A1 (en) 3,4,5-trimethoxybenzamidocarboxylic acids and their salts and medicinal preparations
DE69937574T2 (en) USE OF THE PHARMACEUTICAL PREPARATION "HISTOCHROME" FOR THE TREATMENT OF ACUTE HERZINFARKTS AND ISCHEMIC ILLNESSES
DE2633891C2 (en) Tris (hydroxymethyl) aminomethane salt of 2- (5-benzoylthienyl) -α-methyl acetic acid, process for its preparation and pharmaceutical compositions containing it
DE3844046A1 (en) Pharmaceutical compositions which contain isomers of hydroxylysine or lysine

Legal Events

Date Code Title Description
PL Patent ceased